Merz gets European approval for Xeomin to treat chronic sialorrhea in adults
Xeomin is claimed to be the first and only neurotoxin with this approved indication in the EU. It secured approval from the US Food and Drug Administration (FDA)
The designation has been granted for Pomalyst to treat patients with HIV-positive Kaposi sarcoma who have previously received systemic chemotherapy, in addition to patients with HIV‐negative Kaposi’s sarcoma.